Skip to main content
. 2020 Jan 23;10:9. doi: 10.3389/fonc.2020.00009

Figure 1.

Figure 1

Soluble PD-L1 measurements in study subjects. (A) sPD-L1 overexpression in the serum of patients with glioma compared with that of meningioma patients and HCs. (B) sPD-L1 levels in the CSF of patients with glioma or meningioma. (C) sPD-L1 measurements in the serum of patients with high- or low-grade glioma. (D) sPD-L1 measurements in the CSF of patients with high- or low-grade glioma. (E) sPD-L1 measurements in the serum of patients with different pathological types of glioma. (F) sPD-L1 measurements in the CSF of patients with different pathological types of glioma. For simplicity, only significant differences are shown. The red horizontal lines within the data signify the medians. Statistical significance was defined as *p < 0.05 or ***p < 0.001.